Login to Your Account

Shield Launches Phase III of Ferric Iron Drug in Anemia

By Nuala Moran

Thursday, October 13, 2011
LONDON – Shield Therapeutics Ltd. dosed the first patients in two Phase III studies of its lead product, ST10, for the treatment of iron deficiency anemia, just four months after closing its first round of venture funding.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription